Analyst Price Target is $19.50
▲ +4.39% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Tango Therapeutics in the last 3 months. The average price target is $19.50, with a high forecast of $27.00 and a low forecast of $14.00. The average price target represents a 4.39% upside from the last price of $18.68.
Current Consensus is
Moderate Buy
The current consensus among 11 investment analysts is to moderate buy stock in Tango Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Read More
